Sanguine's PHER-O2 blood substitute may have diabetes applications

By Angela McDaniels

Seattle, Feb. 7 - Sanguine Corp. said an international medical group has found a new scientific approach whereby the company's PHER-O2 blood substitute would be used to increase oxygenation to the small vessels that supply blood to critical areas of the body affected by type 2 diabetes.

"The Sanguine product, PHER-O2, has long been viewed by us as a blood substitute. However, when considering the oxygen-carrying capacity associated with the product's predecessor, FDA-approved Fluosol, it's reasonable that PHER-O2 could be beneficial to many medical situations where increased oxygen into the microvascular system is desired," Robert Kwun, who is evaluating the new approach for Sanguine, said in a company news release.

"The worldwide market for diabetic therapies, both type 1 and type 2, is huge," president and chief executive officer Thomas C. Drees said in the release.

"According to industry sources, the diabetes market is believed to top $10 billion annually and growing. We are anxious and happy to consider any science where PHER-O2 may play a beneficial role in diabetic medical therapies," Drees added in the release.

Sanguine is a biopharmaceutical company based in Pasadena, Calif., that develops oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.